Skip to main content
OpenTrials
Completed

NCT Number: NCT03037606

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets

It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in patients with Gastroesophageal Reflux Disease (GERD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ege University Facult of Medicine Gastroenterology Department

Izmir, 35100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) at least 1 or more episodes a week.
  • Age ≥ 18 years and <65 years
  • Helicobacter pylori (an infection) negative
  • Have a body mass index (BMI) between 18 and 33 kg/m²
  • pH>4 gastric exposure <25% on a 24-hour dual pH channel monitoring study performed prior to screening (normal intragastric pH +2SD)
  • Pathologic intraesophageal acidity exposure (DeMeester score >14.75 and/or >4% of pH<4 (at least 21 hours measured)

Exclusion criteria

  • Patiets with Barrett's stricture, gastric outlet obstruction, malignancy, gastrointestinal system bleeding or any other upper gastrointestinal system pathology.
  • Patients whose Hiatus hernia is > 3 cm.
  • Patients with uncontrolled or insulin dependent diabetes mellitus, symptomatic gallbladder stone, active or unhealed stomach or duodenum ulcer, Zollinger-Ellison syndrome, primary esophagus motility disorder, pancreatitis, inflammatory bowel disease, severe lung disease, chronic liver disease, uncontrolled kidney impairment, cancer (except skin cancer except melanoma), cerebrovascular disease, epilepsy.
  • Patients with history of heart failure, ventricular tachycardia, ventricular fibrillation, cardiac arrest, Torsades de pointes, bradycardia, sinus node dysfunction, heart attack, long QTc (>450 ms for male, >470 ms for female patients).
  • Patients taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before entering the study.
  • Patients with major psychiatric disease.
  • Alcoholism and drug use.
  • Patients with pathologic laboratory tests; hemogram, sedimentation, CRP, thyroid functions tests, liver enzymes.
  • Malabsorbtion.
  • Immunosuppressive patients.
  • Patients taken cortisone.
  • Patients taken other drugs that prolong QT interval.
  • Patients taken drugs that need gastric acid for optimal absorption; ketoconazole, iron salts, digoxin, ampicillin esters, anticoagulants, antineoplastic agents, prostaglandin analogues, sukralfat.
  • Pregnancy or breast-feeding.
  • Patients taken drugs that may affect gastrointestinal system motility or acid release.
  • History of abdominal surgery (hysterectomy, abdominal hernia repair, caesarean cases may be included; cholecystectomy have to be excluded).
  • Patients taken NSAII drugs (paracetemol may be used up to 2 gr/day).
  • Patients taken antidepressants.
  • Hypersensitivty to study drugs.
  • Known allergy to peanut and soy.

Treatment and study plan

Rabelis DDR 50 mg Capsules

Drug

Rabelis DDR 50 mg Capsules once daily for seven days.

Pariet 20 mg Enteric Coated Tablets

Drug

Pariet 20 mg Enteric Coated Tablets once daily for seven days.

Primary outcomes

  1. Percentage time of 24-hour intragastric pH >4 compared to baseline

    Time frame: 7 days

  2. AUC of 24-hour intragastric pH >4 compared to baseline

    Time frame: 7 days

Secondary outcomes

  1. Significant increase in total measurements of median pH

    Time frame: 7 days

  2. Significant increase in nocturnal measurements of median pH

    Time frame: 7 days

  3. Decrease in reflux symptom index calculated by weekly regurgitation numbers

    Time frame: 7 days

  4. Decrease in reflux symptom index calculated by weekly pyrosis numbers

    Time frame: 7 days

  5. Percentage time of 24-hour intragastric pH >2 compared to baseline

    Time frame: 7 days

  6. Percentage time of 24-hour intragastric pH >6 compared to baseline

    Time frame: 7 days

  7. AUC of 24-hour intragastric pH >2 compared to baseline

    Time frame: 7 days

  8. AUC of 24-hour intragastric pH >6 compared to baseline

    Time frame: 7 days

  9. Percentage time of 24-hour total intragastric pH >4 compared to baseline

    Time frame: 7 days

  10. AUC of 24-hour total intragastric pH >4 compared to baseline

    Time frame: 7 days

  11. Percentage time of 24-hour total intragastric pH >4 between 11 pm and 7 am compared to baseline baseline

    Time frame: 7 days

    rate of night reflux

  12. AUC of of 24-hour total intragastric pH >4 between 11 pm and 7 am compared to baseline

    Time frame: 7 days

    rate of night reflux

  13. The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatments)

    Time frame: 7 days

  14. Change in QT interval obtained by ECG compared to baseline

    Time frame: 21 days

Sponsors and collaborators

Lead sponsor

Neutec Ar-Ge San ve Tic A.Ş

Industry

Registry information

Official study title

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jan 31, 2017
Registry last updated
Dec 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.